A quiescence-like/TGF-β1-specific CRISPRi screen reveals drug uptake transporters as secondary targets of kinase inhibitors in AML
Drug Resistance Updates · 2025
DOI: 10.1016/j.drup.2025.101242 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2025. Verfasst von Elahe Rahimian und 17 weiteren Autor:innen. Beteiligte Einrichtung: Mildred Scheel Early Career Center, National Center for Tumor Diseases (NCT/UCC) Dresden, Faculty of Medicine and University Hospital Carl Gustav Car…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Transforming Growth Factor beta1, Protein Kinase Inhibitors, Equilibrative Nucleoside Transporter 1. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bundesministerium für Bildung und Forschung, Technische Universität Dresden, German Cancer Aid.
Abstract (Originalsprache)
Relapse in acute myeloid leukemia (AML) is driven by resistant subclones that survive chemotherapy. It is assumed that these resilient leukemic cells can modify their proliferative behavior by entering a quiescent-like state, similar to healthy hematopoietic stem cells (HSCs). These dormant cells can evade the effects of cytostatic drugs that primarily target actively dividing cells. Although quiescence has been extensively studied in healthy hematopoiesis and various solid cancers, its role in AML has remained unexplored. In this study, we applied an HSC-derived quiescence-associated gene signature to an AML patient cohort and found it to be strongly correlated with poor prognosis and active TGF-β signaling. In vitro treatment with TGF-β1 induces a quiescence-like phenotype, resulting in a G0 shift and reduced sensitivity to cytarabine. To find potential therapeutic targets that prevent AML-associated quiescence and improve response to cytarabine, we conducted a comprehensive CRISPR interference (CRISPRi) screen combined with TGF-β1 stimulation. This approach identified TGFBR1 inhibitors, like vactosertib, as effective agents for preventing the G0 shift in AML cell models. However, pretreatment with vactosertib unexpectedly induced complete resistance to cytarabine. To elucidate the underlying mechanism, we performed a multi-faceted approach combining a second CRISPRi screen, liquid chromatography-tandem mass spectrometry (LC-MS/MS), and in silico analysis. Our findings revealed that TGFBR1 inhibitors unintentionally target the nucleoside transporter SLC29A1 (ENT1), leading to reduced intracellular cytarabine levels. Importantly, we found that this drug interaction is not unique to TGFBR1 inhibitors, but extends to other clinically significant kinase inhibitors, such as the FLT3 inhibitor midostaurin. These findings may have important implications for optimizing combination therapies in AML treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mildred Scheel Early Career Center, National Center for Tumor Diseases (NCT/UCC) Dresden, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany; Department…
- Institute for Clinical Chemistry and Laboratory Medicine, TU Dresden, Dresden, Germany.
- Biotechnology Center (BIOTEC), Center for Molecular and Cellular Bioengineering, Technische Universität Dresden, Dresden, Germany.
- Core Unit for Molecular Tumor Diagnostics (CMTD), National Center for Tumor Diseases Dresden (NCT), NCT/UCC Dresden, a partnership between German Cancer Research Center (DKFZ), Faculty of Medicine and University Hospita…
- Institute for Clinical Genetics, University Hospital Carl Gustav Carus at TUD Dresden University of Technology and Faculty of Medicine of TUD Dresden University of Technology, Dresden, Germany; ERN GENTURIS, Hereditary…
- Department of Pediatric Hematology and Oncology, University Hospital Dresden, Dresden, Germany.
Förderung
- Bundesministerium für Bildung und Forschung
- Technische Universität Dresden
- German Cancer Aid
- German Research Foundation
Zitieren
APA
Rahimian, E., Koochak, M., Traikov, S., Schroeder, M., Brilloff, S., Schäfer, S., Kufrin, V., Küchler, S., Krüger, A., Mirtschink, P., Baretton, G., Schröck, E., Schewe, D. M., Ball, C. R., Bornhäuser, M., Glimm, H., Bill, M., & Wurm, A. A. (2025). A quiescence-like/TGF-β1-specific CRISPRi screen reveals drug uptake transporters as secondary targets of kinase inhibitors in AML. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2025.101242
Vancouver
Rahimian E, Koochak M, Traikov S, Schroeder M, Brilloff S, Schäfer S, et al. A quiescence-like/TGF-β1-specific CRISPRi screen reveals drug uptake transporters as secondary targets of kinase inhibitors in AML. Drug Resistance Updates. 2025. doi:10.1016/j.drup.2025.101242
BibTeX
@article{Rahimian2025,
author = {Rahimian, Elahe and Koochak, Masoud and Traikov, Sofia and Schroeder, Michael and Brilloff, Silke and Schäfer, Silvia and Kufrin, Vida and Küchler, Sandra and Krüger, Alexander and Mirtschink, Peter and Baretton, Gustavo and Schröck, Evelin and Schewe, Denis M and Ball, Claudia R and Bornhäuser, Martin and Glimm, Hanno and Bill, Marius and Wurm, Alexander A},
title = {A quiescence-like/TGF-β1-specific CRISPRi screen reveals drug uptake transporters as secondary targets of kinase inhibitors in AML},
journal = {Drug Resistance Updates},
year = {2025},
doi = {10.1016/j.drup.2025.101242}
}
EUVIMED